MedTrace Logo

Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

NCT04883125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-05-12

No results posted yet for this study

Summary

Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.

Conditions

  • Chronic Myelogenous Leukemia, BCR-ABL Positive
  • CML, Chronic Phase

Interventions

DRUG

Pioglitazone 15mg

pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Mohamed N. Mabed, Professor · Oncology Center Mansoura University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-04-15
Completion
2021-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883125 on ClinicalTrials.gov